Innate Pharma S.A is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Press Releases
4-May-21

Innate Pharma Announces Conference Call and Webcast for 2021 First Quarter Business Update

MARSEILLE, France, May 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, May 11, 2021 at 3 p.m. CEST / 9 a.m.

28-Apr-21

Innate Pharma Files its 2020 Universal Registration Document (Document d'Enregistrement Universel) and 2020 Annual Report on Form 20-F

Marseille, France, April 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2020 Universal Registration Document ( Document d’enregistrement universel ) for the year ending

21-Apr-21

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 28, 2021

The Annual General Meeting will be broadcasted live by the Company Shareholders are invited to vote at the General Meeting either by mail or by proxy MARSEILLE, France , April 21, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “